Phase II Trials in Drug Development and Adaptive Trial Design von Van Norman, Gail A., MD

Volltext

Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? von Van Norman, Gail A

Volltext

Self-reported functional status predicts post-operative outcomes in non-cardiac surgery patients with pulmonary hypertension von Shah, Aalap C, Ma, Kevin, Faraoni, David, Oh, Daniel C S, Rooke, G Alec, Van Norman, Gail A

Volltext

Keeping the Patient at the Center of Conscientious Objection while Respecting Our Colleagues von Lucero, Jennifer, Van Norman, Gail A

Volltext

Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs von Van Norman, Gail A

Volltext

Limitations of Animal Studies for Predicting Toxicity in Clinical Trials Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials von Van Norman, Gail A.

Volltext

Decentralized Clinical Trials The Future of Medical Product Development? von Van Norman, Gail A.

Volltext

Drugs and Devices: Comparison of European and U.S. Approval Processes von Van Norman, Gail A

Volltext

Limitations of Animal Studies for Predicting Toxicity in Clinical Trials von Van Norman, Gail A.

Volltext

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices von Van Norman, Gail A

Volltext

Off-Label Use vs Off-Label Marketing of Drugs: Part 1: Off-Label Use-Patient Harms and Prescriber Responsibilities von Van Norman, Gail A

Volltext

Expanding Patient Access to Investigational Drugs von Van Norman, Gail A., MD

Volltext

Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics von Van Norman, Gail A., MD

Volltext

Off-Label Use vs Off-Label Marketing: Part 2: Off-Label Marketing-Consequences for Patients, Clinicians, and Researchers von Van Norman, Gail A

Volltext

Data Safety and Monitoring Boards Should Be Required for Both Early- and Late-Phase Clinical Trials von Van Norman, Gail A.

Volltext

Drugs and Devices von Van Norman, Gail A., MD

Volltext

Update to Drugs, Devices, and the FDA How Recent Legislative Changes Have Impacted Approval of New Therapies von Van Norman, Gail A.

Volltext

Drugs, Devices, and the FDA: Part 2 von Van Norman, Gail A., MD

Volltext

Technology Transfer: From the Research Bench to Commercialization: Part 2: The Commercialization Process von Van Norman, Gail A, Eisenkot, Roï

Volltext

Drugs, Devices, and the FDA: Part 1 von Van Norman, Gail A., MD

Volltext